Compare Cytokinetics Inc (CYTK) vs iShares Gold Trust (IAU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares Gold Trust — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while iShares Gold Trust trades at $78.87 (market cap $61.51B). The key difference: iShares Gold Trust is far larger — about 7.1× Cytokinetics Inc's market cap, and iShares Gold Trust is more actively traded (3,206,729 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares Gold Trust for 49 Days on average.
| CYTK | IAU | |
|---|---|---|
Market Cap | $8.62B | $61.51B |
Volume | 2,594,626 | 3,206,729 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $87.26 | $101.57 |
52-Week Low | $54.76 | $74.21 |
Typical Hold Time | 19 Days | 49 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
IAU stock trades at $77.66 with a modest 0.78% daily gain amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend while oscillators remain neutral. Recent news highlights gold's sensitivity to interest rate expectations and Treasury yield movements, with mixed sentiment from financial media regarding near-term prospects.
The outlook remains cautious with technical indicators favoring sellers, though oversold conditions could present tactical opportunities. Key risks include persistent rate hike expectations and dollar strength, while institutional positioning suggests defensive sentiment prevails in the current macroeconomic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →
